This ADC has shown robust anti-tumor activity in patient-derived xenografts with a range of FRα expression levels.91 A Phase 1/2a study of AZD5335 (FONTANA, NCT05797168) is currently recruiting. Here, FOLR1 is linked to neoplasm.